Catherine Lumley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine Lumley has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Trevor Hackman
Department of Otolaryngology University of North Carolina‐Chapel Hill Chapel Hill USA
2 shared publications Adam M. Zanation
Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.
1 shared publicationAdam Zanation
Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine
1 shared publicationAndrew F. Olshan
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.
1 shared publication- Andrew J. Coniglio
Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine
1 shared publication - Bhishamjit S. Chera
Hollings Cancer Center, Medical University of South Carolina Charleston South Carolina USA
1 shared publication
Latest Publications
- 11 March 2021
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 44 (5) , 200-205
Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma
Objective: The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation. Results: Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged. Conclusion: Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates. Level of Evidence: Level III—retrospective cohort study.
- 11 March 2021
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 44 (5) , 200-205
Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma
Objective: The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation. Results: Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged. Conclusion: Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates. Level of Evidence: Level III—retrospective cohort study.
- 25 May 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (2) , E479-E488
Academic Affiliation and Surgical Volume Predict Survival in Head and Neck Cancer Patients Receiving Surgery
Objective: To determine whether the academic affiliation or surgical volume affects the overall survival (OS) of human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) patients receiving surgery.Methods: A retrospective study of 39 North Carolina Medical Centers was conducted. Treatment centers were classified as academic hospitals, community cancer centers, or community hospitals and were divided into thirds by volume. The primary outcome was 5‐year OS. Hazard ratios (HR) were determined using Cox proportional hazard models, adjusting for demographics, tumor site, stage, insurance status, tobacco use, alcohol use, stage, chemotherapy, and radiation therapy. Patients were also stratified by stage (early stage and advanced stage).Results: Patients treated at community cancer centers had significantly better 5‐year OS (HR 0.68, 95% confidence interval [CI] = 0.48–0.98), and patients treated at academic hospitals trended toward better 5‐year OS (HR 0.72, 95% CI = 0.50–1.04) compared to patients treated at community hospitals. The effect for academic affiliation on survival was more pronounced for patients with advanced stage cancer at diagnosis (HR 0.60, 95% CI = 0.37–0.95). There were no significant survival differences among early stage patients by treatment center type. Top‐third (HR = 0.64, 95% CI = 0.42–0.96) centers by surgical volume had significantly better 5‐year OS, and middle‐third (HR = 0.71, 95% CI = 0.51–1.03) centers by volume trended toward better 5‐year OS when compared to the bottom‐third centers by volume.Conclusion: Patients treated at academic hospitals, community cancer centers, and hospitals in the top third by case volume have favorable survival for HPV‐negative HNSCC. The effect for academic hospitals is most pronounced among advanced stage patients.Level of Evidence: 4 Laryngoscope, 131:E479–E488, 2021
- 25 May 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (2) , E479-E488
Academic Affiliation and Surgical Volume Predict Survival in Head and Neck Cancer Patients Receiving Surgery
Objective: To determine whether the academic affiliation or surgical volume affects the overall survival (OS) of human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) patients receiving surgery.Methods: A retrospective study of 39 North Carolina Medical Centers was conducted. Treatment centers were classified as academic hospitals, community cancer centers, or community hospitals and were divided into thirds by volume. The primary outcome was 5‐year OS. Hazard ratios (HR) were determined using Cox proportional hazard models, adjusting for demographics, tumor site, stage, insurance status, tobacco use, alcohol use, stage, chemotherapy, and radiation therapy. Patients were also stratified by stage (early stage and advanced stage).Results: Patients treated at community cancer centers had significantly better 5‐year OS (HR 0.68, 95% confidence interval [CI] = 0.48–0.98), and patients treated at academic hospitals trended toward better 5‐year OS (HR 0.72, 95% CI = 0.50–1.04) compared to patients treated at community hospitals. The effect for academic affiliation on survival was more pronounced for patients with advanced stage cancer at diagnosis (HR 0.60, 95% CI = 0.37–0.95). There were no significant survival differences among early stage patients by treatment center type. Top‐third (HR = 0.64, 95% CI = 0.42–0.96) centers by surgical volume had significantly better 5‐year OS, and middle‐third (HR = 0.71, 95% CI = 0.51–1.03) centers by volume trended toward better 5‐year OS when compared to the bottom‐third centers by volume.Conclusion: Patients treated at academic hospitals, community cancer centers, and hospitals in the top third by case volume have favorable survival for HPV‐negative HNSCC. The effect for academic hospitals is most pronounced among advanced stage patients.Level of Evidence: 4 Laryngoscope, 131:E479–E488, 2021
- 11 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (5) , 1220-1226
Post‐diagnosis aspirin use and survival in veterans with head and neck cancer
Background: Our objective was to determine the effect of post‐diagnosis aspirin use on survival in veterans with head and neck squamous cell carcinoma.Methods: Retrospective cohort study of 584 veterans with head and neck squamous cell carcinoma treated at the Washington DC VA Medical Center between 1995 and 2015. Charts were queried for clinical‐pathologic data, aspirin prescriptions, and outcome. The Kaplan–Meier method was used to determine overall survival (OS) and disease‐specific survival (DSS) among aspirin users and nonusers.Results: A total of 329 patients met inclusion criteria. Primary subsites included oropharynx (n = 143), larynx (n = 105), oral cavity (n = 62), and hypopharynx (n = 19). Eighty‐four patients were aspirin users (25.5%). Aspirin users demonstrated significantly better 3‐year OS and DSS (78.6% and 88.1%) compared to nonaspirin users (OS: 55.9% and DSS: 70.2%; P = .0003 and P = .0019, respectively). On multivariate analysis, aspirin use remained independently associated with improved survival.Conclusion: Aspirin use following diagnosis and curative treatment of head and neck squamous cell carcinoma is associated with improved OS and DSS.
- 11 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (5) , 1220-1226
Post‐diagnosis aspirin use and survival in veterans with head and neck cancer
Background: Our objective was to determine the effect of post‐diagnosis aspirin use on survival in veterans with head and neck squamous cell carcinoma.Methods: Retrospective cohort study of 584 veterans with head and neck squamous cell carcinoma treated at the Washington DC VA Medical Center between 1995 and 2015. Charts were queried for clinical‐pathologic data, aspirin prescriptions, and outcome. The Kaplan–Meier method was used to determine overall survival (OS) and disease‐specific survival (DSS) among aspirin users and nonusers.Results: A total of 329 patients met inclusion criteria. Primary subsites included oropharynx (n = 143), larynx (n = 105), oral cavity (n = 62), and hypopharynx (n = 19). Eighty‐four patients were aspirin users (25.5%). Aspirin users demonstrated significantly better 3‐year OS and DSS (78.6% and 88.1%) compared to nonaspirin users (OS: 55.9% and DSS: 70.2%; P = .0003 and P = .0019, respectively). On multivariate analysis, aspirin use remained independently associated with improved survival.Conclusion: Aspirin use following diagnosis and curative treatment of head and neck squamous cell carcinoma is associated with improved OS and DSS.